Cerevel Therapeutics Holdings Inc Revenue Growth Rates (CERE), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Cerevel Therapeutics Holdings Inc   (NASDAQ: CERE)
 

CERE's Revenue Growth by Quarter and Year

Cerevel Therapeutics Holdings Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

CERE Revenue (in millions $) FY 2024 FY 2023 FY 2022 FY 2021
4th Quarter December -
3rd Quarter September -
2nd Quarter June -
1st Quarter March 0.00
FY 0.00

CEREs Annual Revenue
Cerevel Therapeutics Holdings Inc 's Revenue in the fiscal year 2023 $ 0.00 millions
Cerevel Therapeutics Holdings Inc 's Revenue in the fiscal year 2022 $ 0.00 millions
Cerevel Therapeutics Holdings Inc 's Revenue in the fiscal year 2021 $ 0.00 millions
Cerevel Therapeutics Holdings Inc 's Revenue in the fiscal year 2020 $ 0.00 millions
Cerevel Therapeutics Holdings Inc 's Revenue in the fiscal year 2015 $ 2.72 millions




CERE Revenue first quarter 2024 Y/Y Growth Comment
Cerevel Therapeutics Holdings Inc in the first quarter 2024 recorded of $ 0.00 millions.

According to the results reported in the first quarter 2024, Cerevel Therapeutics Holdings Inc achieved the best Revenue growth in Major Pharmaceutical Preparations industry. While Cerevel Therapeutics Holdings Inc ' s Revenue no change of 0% ranks overall at the positon no. in the first quarter 2024.


CERE Revenue ( Y/Y Growth %) 2024
 2023 2022 2021
4th Quarter December - - - -
3rd Quarter September - - - -
2nd Quarter June - - - -
1st Quarter March - - - -
FY   - - - -

Financial Statements
Cerevel Therapeutics Holdings Inc 's first quarter 2024 Revenue $ 0.00 millions CERE's Income Statement
Cerevel Therapeutics Holdings Inc 's first quarter 2023 Revenue $ 0.00 millions Quarterly CERE's Income Statement


CERE Revenue (Quarter on Quarter Growth %)

 2024
 2023 2022 2021
4th Quarter December - - - -
3rd Quarter September - - - -
2nd Quarter June - - - -
1st Quarter March - - - -
FY (Year on Year)   - - - -


Back to CERE Growth rate Comparisons >> Back to CERE Growth rate Comparisons >>


Revenue first quarter 2024 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Revenue Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 
Revenue first quarter 2024 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Revenue Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 

Revenue by Quarter for the Fiscal Years 2021, 2022, 2023, 2024

Cerevel Therapeutics Holdings Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


CERE's I. Quarter Q/Q Revenue Comment


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Revenue Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


CERE's I. Quarter Q/Q Revenue Comment


Cerevel Therapeutics Holdings Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Mar 31 2024)		 12 Months Ending
(Dec 31 2023)		 12 Months Ending
(Sep 30 2023)		 12 Months Ending
(Jun 30 2023)		 12 Months Ending
(Mar 31 2023)
Cumulative Revenue 12 Months Ending $ 0.00 $ 0.00 $ 0.00 $ 0.00 $ 0.00
Y / Y Revenue Growth (TTM) - - - - -
Year on Year Revenue Growth Overall Ranking # # # # #
Seqeuential Revenue Change (TTM) - - - - -
Seq. Revenue Growth (TTM) Overall Ranking # # # # #


Cumulative Revenue growth Comment
In the Mar 31 2024 period, Cerevel Therapeutics Holdings Inc 's cumulative trailing twelve month Revenue remained unchanged compare to the same period a year ago.

Cerevel Therapeutics Holdings Inc achieved highest trailing twelve month year on year Revenue growth. While overall Revenue growth ranking, remained unchanged compare to the previous quarter at no. .

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Revenue TTM Y/Y Growth Statistics
High Average Low
0 %
 0 %
0 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #
Cumulative Revenue growth Comment
In the Mar 31 2024 period, Cerevel Therapeutics Holdings Inc 's cumulative trailing twelve month Revenue remained unchanged compare to the same period a year ago.

Cerevel Therapeutics Holdings Inc achieved highest trailing twelve month year on year Revenue growth. While overall Revenue growth ranking, remained unchanged compare to the previous quarter at no. .


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Revenue TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 






Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
CERE's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue no change for the quarter ending Mar 31 2024 within Healthcare SectorY/Y Change %Revenue for the quarter ending Mar 31 2024
Collegium Pharmaceutical Inc -0.21%$ -0.215 millions
Mettler toledo International Inc -0.30%$ -0.300 millions
Icu Medical Inc-0.42%$ -0.423 millions
Lifeloc Technologies Inc -0.51%$ -0.513 millions
Regeneron Pharmaceuticals Inc -0.54%$ -0.541 millions
Envista Holdings Corporation-0.62%$ -0.622 millions
3m Company-0.64%$ -0.644 millions
Orgenesis Inc -0.70%$ -0.704 millions
T2 Biosystems Inc -0.82%$ -0.818 millions
Vyne Therapeutics Inc -1.01%$ -1.010 millions
Enhabit Inc -1.02%$ -1.018 millions
Valneva Se-1.11%$ -1.112 millions
Ge Healthcare Technologies Inc -1.50%$ -1.502 millions
Baxter International Inc -1.56%$ -1.562 millions
Y mabs Therapeutics inc -1.58%$ -1.580 millions
Pacific Biosciences Of California Inc -1.59%$ -1.589 millions
Cartesian Therapeutics Inc -1.65%$ -1.650 millions
Viatris Inc -1.76%$ -1.762 millions
Zimvie Inc -1.84%$ -1.836 millions
Sight Sciences Inc -1.87%$ -1.870 millions
Opus Genetics Inc -2.17%$ -2.173 millions
Vaso Corporation-2.51%$ -2.513 millions
Dentsply Sirona Inc -2.56%$ -2.556 millions
Alpha Pro Tech Ltd -2.78%$ -2.775 millions
Prestige Consumer Healthcare Inc -2.82%$ -2.817 millions
West Pharmaceutical Services Inc -2.99%$ -2.986 millions
Wave Life Sciences Ltd -3.02%$ -3.024 millions
Fulgent Genetics Inc -3.12%$ -3.119 millions
Integra Lifesciences Holdings Corp-3.14%$ -3.144 millions
Accelerate Diagnostics Inc -3.17%$ -3.165 millions


About Cerevel Therapeutics Holdings Inc Revenue Growth Rates (CERE), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: the company’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.